Impact of the <scp>COVID</scp>‐19 pandemic on biologic treatment in psoriasis patients: A single‐center retrospective study in Japan

Uchida, Hideaki; Kamata, Masahiro; Egawa, Shota; Nagata, Mayumi; Fukaya, Saki; Hayashi, Kotaro; Fukuyasu, Atsuko; Tanaka, Takamitsu; Ishikawa, Takeko; Ohnishi, Takamitsu; Tada, Yayoi

doi:10.1111/1346-8138.16362

Cited by 5 publications

(5 citation statements)

References 6 publications

(9 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…31–33 These results are consistent with similar observations from Japan, Canada, and some European countries, where a reduced number of patients (between 1.2% and 6.0%) discontinued systemic treatment. 26 , 34–40 Our survey revealed a quite relaxed and unworried perception of patients with psoriasis, mostly unaffected by the pandemics regarding conduct of medication which is in line with national and international recommendations of the Medical Societies. 31–33 Only a reduced number of patients discontinued their systemic therapies (2.7% and 1.7% of the total cohorts in the years 2020 and 2022, respectively).…”

Section: Discussionsupporting

confidence: 76%

See 1 more Smart Citation

Perception and Impact of COVID-19 Pandemic in Psoriasis Patients: Data from the German PsoBest and the CoronaBest Registries

Valencia López,

Stephan,

Meineke

et al. 2024

PTT

View full text Add to dashboard Cite

Background: Limited data are available characterizing the impact of the SARS-CoV-2 pandemic on psoriasis care for patients in Germany.Objective: To analyze patient perception and impact of the pandemic on well-being and psoriasis management of German patients with moderate-to-severe psoriasis or psoriasis arthritis under systemic therapies. Methods: The CoronaBest registry captures events of SARS-CoV-2 infections and analyzes the impact of the pandemic on patients with psoriasis or psoriasis arthritis. In June 2020, and independently in February 2022, patients with psoriasis or psoriasis arthritis received a standardized questionnaire for current treatment, protective measures, well-being, and individual risks for COVID-19, among others. Results: Included were 4,194 patients in 2020 (mean age of 47.7 years and 41.8% women) and 4,818 patients in 2022 (mean age of 56.4 and 42.9% women). Treatment discontinuations were observed in 2.7% and 1.7% of patients in 2020 and 2022, respectively. In the vast majority of the cases (>92%), no additional measures were taken concerning the management of psoriasis treatments in either 2020 or 2022. Those patients with changes reported most frequently: telephone calls instead of face-to-face visits (80.2%, in 2020 vs 40.5% in 2022) or more frequent controls (27.1%, 2020 vs 22.0%, 2022). A majority (66.7%, 2020, and 70.6%, 2022) did not perceive the virus as a considerable threat. The proportion of patients feeling well informed about COVID-19 by physicians increased from 42.6% in 2020 to 51.8% in 2022. About 81.1% of patients in 2020 and 67.5% in 2022 stated that their overall personal condition was not affected due to the pandemic. Physicians attributed no special risk of contracting SARS-CoV-2 in most of the patients. Conclusion: A high rate of systemic treatment persistence and awareness of risks and protective measures indicate that health care for psoriasis largely followed current national and international recommendations during the COVID-19 pandemic.

show abstract

Section: Discussionsupporting

confidence: 76%

“…[31][32][33] These results are consistent with similar observations from Japan, Canada, and some European countries, where a reduced number of patients (between 1.2% and 6.0%) discontinued systemic treatment. 26,[34][35][36][37][38][39][40] Our survey revealed a quite relaxed and unworried…”

Section: Discussionmentioning

confidence: 89%

Perception and Impact of COVID-19 Pandemic in Psoriasis Patients: Data from the German PsoBest and the CoronaBest Registries

Valencia López,

Stephan,

Meineke

et al. 2024

PTT

View full text Add to dashboard Cite

show abstract

“…Termination of therapy was reported by only 3% of the patients, without relevant changes compared to what reported before the national lockdown, with results that were independent from the type of rheumatic diseases, the immunomodulatory therapy, and the age of patients. In the study by Uchida et al [21], assessing discontinuation of biologics in patients with psoriasis, defined as ceasing biologic treatment and never receiving any biologic treatment at least until July 2021, 2.8% of patients discontinued biologic treatment in 2020, compared to 0.6% in 2019.…”

Section: Resultsmentioning

confidence: 99%

“…However, according to a systematic review addressing the frequency and reasons for the disruption of care for inflammatory bowel disease patients [60], the pooled rate of adherence failure with this therapy was 10.12 (CI, 7.12-14.18) per 100 patients, mainly driven by concerns regarding safety amongst both clinicians and patients [61]. In fact, the reduction in adherence reported in some studies [20,21] seems to be mostly related to the fact that patients with rheumatic diseases believed that the immunosuppression obtained with their treatment increased their risk of being infected with COVID-19 or worsen the severity of the disease, and that stopping treatment might reduce the risk [40,42,62,63]. This issue was promptly addressed through specific recommendations and national guidelines [50,63,64], which contributed to mitigate the problem, with small percentages of subjects who discontinued treatment for this reason, or with cases in which treatment was just postponed [41].…”

Section: Discussionmentioning

confidence: 99%

Impact of COVID-19 Pandemic on Adherence to Chronic Therapies: A Systematic Review

Olmastroni

Galimberti

Tragni

et al. 2023

IJERPH

View full text Add to dashboard Cite

The spread of the coronavirus disease 2019 (COVID-19) pandemic caused a sudden and significant disruption in healthcare services, especially for patients suffering from chronic diseases. We aimed at evaluating the impact of the pandemic on adherence to chronic therapies through a systematic review of available studies. PubMed, EMBASE, and Web of Science were searched since inception to June 2022. Inclusion criteria were: (1) observational studies or surveys; (2) studies on patients with chronic diseases; (3) reporting the effects of COVID-19 pandemic on adherence to chronic pharmacological treatment, as a comparison of adherence during the pandemic period vs. pre-pandemic period (primary outcome) or as rate of treatment discontinuation/delay specifically due to factors linked to COVID-19 (secondary outcome). Findings from 12 (primary outcome) and 24 (secondary outcome) studies showed that many chronic treatments were interrupted or affected by a reduced adherence in the pandemic period, and that fear of infection, difficulty in reaching physicians or healthcare facilities, and unavailability of medication were often reported as reasons for discontinuation or modification of chronic therapies. For other therapies where the patient was not required to attend the clinic, continuity of treatment was sometimes ensured through the use of telemedicine, and the adherence was guaranteed with drug stockpiling. While the effects of the possible worsening of chronic disease management need to be monitored over time, positive strategies should be acknowledged, such as the implementation of e-health tools and the expanded role of community pharmacists, and may play an important role in preserving continuity of care for people with chronic diseases.

show abstract

“…A single-center study by Uchida et al also demonstrated an increase in patients newly diagnosed with GPP from 2019 to 2020. 22 The limited effect of the COVID-19 pandemic on GPP diagnoses likely reflected the life-threatening and systemic nature of GPP in which patients have limited choices other than seeking medical attention.…”

Section: Discussionmentioning

confidence: 99%

Regional differences in the prevalence of generalized pustular psoriasis in Japan

Fujita,

Iwasaki,

Tsuboi

et al. 2024

The Journal of Dermatology

View full text Add to dashboard Cite

Generalized pustular psoriasis (GPP), a rare form of psoriasis, is characterized by neutrophil‐rich, sterile pustules. In Japan, GPP has intractable and rare disease designation, which allows patients to access support from national and local governments for medical expenses. Previously, similar numbers of patients in Tokyo and Hokkaido have been shown to have GPP designation, despite different population sizes. Here, we determine whether there are regional differences in the proportion of patients receiving GPP designation status in Japan and aim to identify causal factors. In this descriptive, retrospective cohort study, publicly available data were collected on the number of patients with intractable and rare disease designation for GPP in each prefecture and age classification (April 2018–March 2021). Three other designated intractable and rare disease cohorts were included: pemphigus, rare skin diseases, and all diseases. The primary outcome was the standardized morbidity ratio (SMR) of patients at prefecture level (observed numbers divided by expected). Regional differences were compared with the statistical expectation for the total population and age distribution of each prefecture. Regional differences were observed in all cohorts. Overall, 1910 patients had GPP as a designated intractable and rare disease in 2020. Regional differences in SMRs for GPP were observed with high SMRs (≥1.5) in Hokkaido, Tottori, Kagawa, and Miyazaki, and low SMRs (<0.6) in Gunma and Kanagawa. Regional differences in SMRs for GPP did not correlate with the number of medical doctors or dermatologists or internal migration. The number of medical doctors or dermatologists correlated with SMRs in the rare skin diseases and total cohorts. Regional differences in Japan exist in the number of patients with GPP who have an intractable and rare disease designation. Managing rare diseases is an important public health issue, and further research is required to elucidate the factors contributing to these differences.

show abstract

Impact of the COVID‐19 pandemic on biologic treatment in psoriasis patients: A single‐center retrospective study in Japan

Cited by 5 publications

References 6 publications

Perception and Impact of COVID-19 Pandemic in Psoriasis Patients: Data from the German PsoBest and the CoronaBest Registries

Perception and Impact of COVID-19 Pandemic in Psoriasis Patients: Data from the German PsoBest and the CoronaBest Registries

Impact of COVID-19 Pandemic on Adherence to Chronic Therapies: A Systematic Review

Regional differences in the prevalence of generalized pustular psoriasis in Japan

Contact Info

Product

Resources

About